EGFR and cancer: The aim of this study was to examine the potential DDIs between rivaroxaban and EGFR TKIs, assess the impact of EGFR TKIs on the metabolism of rivaroxaban in vivo and in vitro, predict the safety of rivaroxaban anticoagulation in cancer patients undergoing EGFR TKI treatment, and offer guidance and support for anticoagulant therapy in these patients.